Table of Contents
Introduction
Top 30 Pharmaceutical Company in Bangladesh 2025 highlights how the pharmaceutical industry in Bangladesh continues to thrive in 2025, reinforcing its position as one of the country’s most dynamic and fast-growing sectors. The industry has become a cornerstone of the national economy and a prominent contributor to the global generics market.
According to IQVIA data for MAT 2Q 2025 (July 2024 – June 2025) and QTR 2Q 2025 (April – June 2025), the Bangladesh pharmaceutical market demonstrated strong and consistent growth.
Market Size: The industry reached a total size of BDT 36,963 crore, marking a solid 12.43% year-on-year (YoY) growth.
Quarterly Performance: In Q2 2025 alone (April – June), the sector generated BDT 9,384 crore in revenue, reflecting a 3.70% growth compared to Q2 2024.
This upward momentum highlights the sector’s resilience and sustainability, driven by:
–Rising domestic demand for medicines
–Greater access to healthcare services across urban and rural areas
–Expanding therapeutic coverage, including anti-diabetic, cardiovascular, oncology, and respiratory segments
Steady growth in pharmaceutical exports
The MAT 2Q 2025 data provides a 12-month snapshot of overall market dynamics, offering insight into long-term performance and trends. On the other hand, the QTR 2Q 2025 data delivers a closer look at quarterly sales patterns, seasonal fluctuations, and short-term shifts in demand. Together, these datasets offer a comprehensive picture of the industry’s current performance and its growth outlook heading into the next fiscal year.
Learn About Top 50 Pharmaceutical Companies In Bangladesh 2025
Market Share Dominance of Top Pharmaceutical Company in Bangladesh
The Bangladeshi pharmaceutical market remains highly consolidated, with a small group of leading players capturing the majority of market revenues. This concentration underscores both the competitiveness and the strategic strength of these companies in distribution, innovation, and brand positioning.
Top 15 Companies Control Almost 90% of the Market
According to MAT 2Q 2025 market data, the top 15 pharmaceutical companies collectively hold approximately 89.06% of the total market share. Together, they dominate nearly the entire BDT 36,963 crore market, highlighting their crucial influence on the country’s healthcare ecosystem.
Top 10 Companies Hold Over Three-Quarters of the Market
Narrowing the focus further, the top 10 pharmaceutical companies account for a significant 75.22% of Bangladesh’s pharmaceutical market. This demonstrates that a relatively small group of industry leaders control the majority of production, sales, and distribution nationwide.
Top 5 Companies Control Over Half of the Market
At the top tier, the top 5 pharmaceutical companies alone command an estimated 53.23% share of the market. This level of concentration emphasizes their leading role in setting market trends, driving therapeutic innovation, and shaping the pricing environment for medicines in Bangladesh.
This distribution pattern clearly illustrates that while Bangladesh’s pharmaceutical sector is vibrant and competitive, a few dominant players hold a commanding position, setting the pace for the industry’s growth and direction.
List of Top 30 Pharmaceutical Company in Bangladesh 2025 (Based on MAT: 2Q-2025 Data)
The following list highlights the Top 30 pharmaceutical companies in Bangladesh according to MAT 2Q-2025 data, which covers the period from July 2024 – June 2025. This ranking reflects market performance, sales revenue, and overall contribution to the Bangladesh pharmaceutical sector.
Understanding MAT 2Q-2025
MAT 2Q-2025 refers to Moving Annual Total market data reported at the end of the second quarter of 2025. It provides a comprehensive 12-month view of the Bangladesh pharmaceutical market, summarizing total sales, growth rate, and company rankings. This data is compiled by IQVIA, the leading global provider of healthcare analytics and market insights.
| Table Data as : MAT: 2Q- 2025, 12 Months (July 2024 – June 2025) | ||||
| Ranking (MAT 2Q-2025) | Company Name | Total value (Cr. BDT) | Market Share (%) | Company Market Growth (%) |
| 1 | SQUARE Pharmaceuticals PLC | 6,434 | 17.407 | +12.99 |
| 2 | Incepta Pharmaceuticals | 4,720 | 12.770 | +20.88 |
| 3 | Beximco Pharmaceuticals Ltd. | 3,537 | 9.569 | -13.37 |
| 4 | Healthcare Pharmaceuticals | 2,859 | 7.735 | +18.60 |
| 5 | Renata PLC | 2,126 | 5.752 | +26.25 |
| 6 | Eskayef Pharmaceuticals Ltd. | 1,829 | 4.948 | +19.14 |
| 7 | Opsonin Pharma | 1,735 | 4.694 | +14.75 |
| 8 | Aristopharma Ltd. | 1,613 | 4.364 | +16.60 |
| 9 | Popular Pharmaceuticals PLC | 1,525 | 4.126 | +30.91 |
| 10 | ACME Laboratories Ltd. | 1,425 | 3.855 | +16.49 |
| 11 | ACI Pharmaceuticals | 1,396 | 3.777 | +17.62 |
| 12 | Radiant Pharmaceuticals Ltd. | 1,360 | 3.679 | +17.06 |
| 13 | Drug International Ltd. | 1,028 | 2.781 | +1.20 |
| 14 | Unimed Unihealth Pharma Ltd. | 863 | 2.335 | -1.20 |
| 15 | Beacon Pharmaceuticals PLC | 468 | 1.266 | -1.66 |
| 16 | NIPRO JMI Pharma Ltd. | 388 | 1.050 | -0.59 |
| 17 | Novo Nordisk | 371 | 1.004 | -24.67 |
| 18 | Ziska Pharmaceuticals Ltd. | 356 | 0.963 | +7.83 |
| 19 | IBNA SINA Pharmaceuticals | 292 | 0.790 | -8.97 |
| 20 | Navana Pharmaceuticals PLC | 284 | 0.768 | +9.75 |
| 21 | Nuvista Pharma Ltd. | 275 | 0.744 | +6.24 |
| 22 | Synovia Pharma PLC | 269 | 0.728 | -1.06 |
| 23 | Roche Bangladesh | 269 | 0.728 | +16.36 |
| 24 | NOVARTIS | 249 | 0.674 | -4.40 |
| 25 | SUN Pharma | 233 | 0.630 | -7.55 |
| 26 | Orion Pharma Ltd. | 203 | 0.549 | -9.23 |
| 27 | General Pharmaceuticals Ltd. | 174 | 0.471 | -57.19 |
| 28 | Eli Lilly | 150 | 0.406 | -4.41 |
| 29 | SERVIER | 145 | 0.392 | -12.20 |
| 30 | SANDOZ | 60 | 0.162 | -21.12 |
| Total Value: | 36,963.0 | 100 % | 12.43 % | |
Data Source: IQVIA MAT 2Q- 2025
List of Top 30 Pharmaceutical Company in Bangladesh 2025 (Based on QTR 2Q-2025 Data)
The following list presents the Top 30 pharmaceutical companies in Bangladesh according to QTR 2Q-2025 data, which covers the three-month period from April 2025 – June 2025. This ranking is based on quarterly market performance, sales revenue, and competitive positioning within the Bangladesh pharmaceutical sector.
Understanding QTR 2Q-2025
QTR 2Q-2025 represents quarterly market data compiled by IQVIA, capturing the pharmaceutical industry’s performance for the latest three-month period ending June 2025. This data provides a focused view of short-term sales patterns, seasonal demand fluctuations, and recent growth trends across therapeutic segments.
| Table Data as : QTR. 2Q- 2025, 3 Months (April 2025 – June 2025) | ||||
| Ranking (QTR. 2Q- 2025) | Company Name | Total value (Cr. BDT) | Market Share (%) | Company Market Growth (%) |
| 1 | SQUARE Pharmaceuticals PLC | 1,601 | 17.061 | -0.35 |
| 2 | Incepta Pharmaceuticals | 1,196 | 12.745 | 9.74 |
| 3 | Beximco Pharmaceuticals Ltd. | 941 | 10.028 | +9.13 |
| 4 | Healthcare Pharmaceuticals | 732 | 7.801 | +9.79 |
| 5 | Renata PLC | 559 | 5.957 | +14.78 |
| 6 | Eskayef Pharmaceuticals Ltd. | 519 | 5.531 | +19.76 |
| 7 | Aristopharma Ltd. | 738 | 7.864 | +13.93 |
| 8 | Opsonin Pharma | 417 | 4.444 | +1.25 |
| 9 | Radiant Pharmaceuticals Ltd. | 387 | 4.124 | +24.27 |
| 10 | Popular Pharmaceuticals PLC | 382 | 4.071 | +7.87 |
| 11 | ACI Pharmaceuticals | 372 | 3.964 | +20.82 |
| 12 | ACME Laboratories Ltd. | 324 | 3.453 | +2.44 |
| 13 | Drug International Ltd. | 275 | 2.931 | +9.00 |
| 14 | Unimed Unihealth Pharma Ltd. | 224 | 2.387 | -6.70 |
| 15 | Beacon Pharmaceuticals PLC | 103 | 1.098 | -29.05 |
| 16 | NIPRO JMI Pharma Ltd. | 83 | 0.884 | -24.49 |
| 17 | Ziska Pharmaceuticals Ltd. | 81 | 0.863 | -18.06 |
| 18 | Novo Nordisk | 78 | 0.831 | -37.50 |
| 19 | Roche Bangladesh | 75 | 0.799 | +24.91 |
| 20 | Nuvista Pharma Ltd. | 69 | 0.735 | -5.58 |
| 21 | Navana Pharmaceuticals PLC | 66 | 0.703 | -11.37 |
| 22 | IBNA SINA Pharmaceuticals | 64 | 0.682 | -22.35 |
| 23 | Synovia Pharma PLC | 63 | 0.671 | -18.21 |
| 24 | NOVARTIS | 59 | 0.629 | -10.44 |
| 25 | SUN Pharma | 59 | 0.629 | -1.29 |
| 26 | Orion Pharma Ltd. | 44 | 0.469 | -25.65 |
| 27 | SERVIER | 36 | 0.384 | -16.45 |
| 28 | Eli Lilly | 33 | 0.352 | -7.60 |
| 29 | General Pharmaceuticals Ltd. | 23 | 0.245 | -73.65 |
| 30 | SANDOZ | 12 | 0.128 | – 40.26 |
| Total Value: | 9,384.0 | 100 % | +3.70 % | |
Remarkable Growth of Roche Pharma and Radiant Pharmaceuticals Limited in QTR 2Q-2025
One of the most notable developments in the QTR 2Q-2025 performance analysis is the exceptional growth demonstrated by Roche Pharma and Radiant Pharmaceuticals Limited. Both companies recorded the highest growth rates among the Top 30 pharmaceutical company in Bangladesh for this quarter.
Roche Pharma achieved an impressive market growth rate of 24.91%, positioning itself as one of the fastest-growing companies in the sector.
Radiant Pharmaceuticals Limited closely followed with a market growth rate of 24.27%, reflecting strong sales momentum and strategic market expansion.
Their growth highlights a broader trend in the Bangladesh pharmaceutical market where smaller but agile players are beginning to capture market share, intensifying competition and diversifying the industry landscape.
What is the Top 20 Pharmaceutical Company in Bangladesh?
Executive Summary
The Bangladesh pharmaceutical market continues to exhibit robust growth and strategic evolution, as highlighted by MAT 2Q-2025 and QTR 2Q-2025 data. Over the past 12 months (July 2024 – June 2025), the market achieved a total size of BDT 36,963 crore, reflecting an impressive 12.43% year-on-year growth.
During the second quarter of 2025 alone (April – June), sales reached BDT 9,384 crore, representing 3.70% growth compared to the same period in 2024. These figures reinforce the industry’s resilience, fueled by increasing chronic care demand, wider healthcare access, and growing export potential.
Market share distribution remains highly concentrated, with the top 15 companies controlling nearly 90% of total revenues and the top 5 players accounting for over half of the market. Industry leaders like Square, Incepta, Healthcare, and Beximco continue to set the pace, while Aristopharma and Eskayef strengthen their positions with competitive growth strategies.
Notably, Roche Pharma (24.91% growth) and Radiant Pharmaceuticals (24.27% growth) recorded the most remarkable quarterly performance among the top 30 companies, signaling a shift where smaller, agile players are increasingly capturing market share.
With strong local manufacturing, favorable regulatory policies, and an industry-wide focus on R&D, Bangladesh is steadily advancing toward becoming a regional and global pharmaceutical hub—poised for deeper participation in biosimilars, novel drug delivery systems, and regulated market exports.
FAQs – Frequently Asked Questions
What is MAT 2Q-2025 in the pharmaceutical market context?
MAT (Moving Annual Total) 2Q-2025 represents cumulative sales and performance data for the 12 months ending in June 2025, offering a comprehensive view of market trends.
What is QTR 2Q-2025?
QTR 2Q-2025 covers market performance for the latest three-month period (April – June 2025), focusing on short-term sales patterns and seasonal demand.
Which are the top 5 pharmaceutical company in Bangladesh in 2025?
According to MAT 2Q-2025 data, the top five companies are Square Pharmaceuticals, Incepta Pharmaceuticals, Beximco Pharmaceuticals, Healthcare Pharmaceuticals and Renata Limited.
What therapeutic segments are driving growth in Bangladesh?
Anti-diabetics, oncology, cardiovascular, respiratory, and chronic care therapies are the key growth drivers.
What is the future outlook for the Bangladesh pharmaceutical industry?
The sector is expected to maintain double-digit growth, driven by expanding exports, investments in biosimilars, and increasing domestic healthcare demand.
Abdus Sobhan Salim is professional experienced pharmacist in pharmaceuticals, author and founder of pharmabossbd.com, the Bangladeshi pharmaceutical blogger since 2019.
